In-House Counsel Forum on Government Regulation of Prescription Drug Pricing

Bill Davis will speak on the panel, "The Status, Evolution and Continued Significance of AWP Litigation," at the 10th Annual In-House Counsel Forum on Government Regulation of Prescription Drug Pricing presented by the American Conference Institute in New York City.

The panel will discuss the following topics:

• Review of the current status of MDL 1465, i.e., In Re Pharmaceutical Average Wholesale Price Litigation
• Examining the effect of AWP litigation on the continued use of the AWP pricing methodology
  - what conclusions have finally been drawn about spread between AWP and actual purchase price?
  - how may these conclusions deter the potential creation of a ‘new spread’ through the use of different pricing methodologies
• Evolution of AWP cases
  - shift from physician administered drugs to self administered drugs
• Update on state AWP cases
  - deciphering how AWP data is still being derived relative to information still supplied from First
  Databank
  - review of state cases which have been brought under different pricing methodologies
  - high profile state AWP actions
• Revisiting the private/public interface in these cases, e.g., suits brought by individuals, unions and consumer groups
  - state consumer protection statutes
  - state false claims act statutes
• Understanding the role of private law firms acting on behalf of state AGs in these matters
• Predicting future trends in the course of these suits

Panel
William A. Davis, Member, Mintz Levin
Michael L. Koon, Partner, Shook, Hardy & Bacon
Katy E. Koski, Partner, K&L Gates

Event Details
The Status, Evolution and Continued Significance of AWP Litigation